✉news ScienceSpace Policy first seen 1 d ago, last 1 d ago, peak #29
ARTEMIS-011 Trial Opens Door to ADCs in Osteosarcoma
Original: Sara Coca Membribes: ARTEMIS-011 Opens the Door to ADCs in Osteosarcoma
Oncologist Sara Coca Membribes says the ARTEMIS-011 trial marks a turning point for antibody-drug conjugate treatment in osteosarcoma, a rare bone cancer with limited options for decades. She argues the trial's results could pave the way for ADCs to become a standard avenue of therapy in this hard-to-treat tumour type.
Why now: New trial data suggesting a promising targeted therapy option for osteosarcoma has drawn attention from oncology specialists.
Sara Coca MembribesARTEMIS-011osteosarcomaantibody-drug conjugates
Rank over time, top of the chart is #1. 4 snapshots from 1 d ago to 1 d ago.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/3964971